MEDIVIR AB – INTERIM REPORT JANUARY – MARCH 2015
Financial summary for the first quarterJanuary – March 2015 (2014) · Net turnover totalled SEK 215.9 million (208.2 m), of which SEK 128.6 million (161.5 m) comprised royalties for simeprevir. · Revenues from Medivir’s own pharmaceutical sales totalled SEK 86.8 million (46.4 m), of which SEK 34.2 million (0.0) derived from sales of OLYSIO® and SEK 52.6 million (46.4 m) from sales of other pharmaceuticals. · The profit after tax was SEK 66.7 million (283.8 m). · Basic and diluted earnings per share totalled SEK 2.29 (9.08) and SEK 2.27 (9.01), respectively. · The cash flow